KAWASAKI, Japan--(BUSINESS WIRE)-- PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the ...
Peptidream Inc. has released promising results from preclinical testing of its oral myostatin inhibitors, administered in combination with semaglutide, in a mouse model of obesity.
- Data support that Scholar Rock’s unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar Rock ...
PeptiDream, the Japanese biopharma with a penchant for deal-making, has a new bargaining chip in its hand in the red-hot obesity space. The firm’s oral macrocyclic peptides preserved lean muscle mass ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
iBio, Inc., an innovator in precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment program by in-licensing a long-acting anti-myostatin antibody, ...
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results